News & Events
Press Releases
On the 28th March 2022, OncoArendi changed its name to Molecure
Molecure Third Quarter 2022 Pipeline Highlights and Financial Results
31 October 2022
Molecure reports continued pipeline momentum for 6 months ended 30th June 2022
29 September 2022
Molecure announces filing of Clinical Trial Application with Polish regulator for OATD-02, a novel dual arginase inhibitor being developed for the treatment of cancer
11 August 2022
Molecure to regain worldwide rights to dual chitinase inhibitor OATD-01
23 June 2022
OncoArendi Therapeutics Reports Continued Strategic and Operational Momentum for 12 Months ended 31 December 2021
25 March 2022
OncoArendi Therapeutics Announces a License Option Agreement with University of Michigan
11 March 2022
Events & Presentations
Fibrosis and Tissue Repair: From Molecules and Mechanics to Therapeutic Approaches – February 19-23, 2020 | Victoria, BC, Canada
27 February 2020
ACS National Meeting & Expo – August 25 – 29, 2019 | San Diego, CA
4 September 2019
EFMC – YMCS – Young Medicinal Chemist Symposium – Ljubljana 02-06.09.2018
17 September 2018